GHRS

GH Research PLC (GHRS) | Rumor.io

GH Research

GHRS

Attention (50-day avg)0%

Attention rank (50-day avg)#1,743

Bullish sentiment (50-day avg)100%

Price to earnings ratio-29.7

Market capitalization1.6B

Earnings per share-0.99

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-48.3M

Social

What share of all stock conversation is about GHRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 17

GH Research PLC (GHRS) had a good move, with a 40-44% increase, and the outlook is promising if they go to market without making a mistake.
The company is developing Ketamir-2, a psychedelic treatment for pain, depression, and anxiety, which is not classified as a controlled substance, making it easier for doctors to prescribe.
The user sold their 10k shares of GHRS and will focus on other stocks, but notes that the company's phase 3 data in Q4 is promising and may lead to a large move.

Generated by AI

Sentiment

Of the messages about GHRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.98% +17.3
Bearish	—	—	0% 0	4.02% -17.3

Bullish· Jan 8

The microcap squeeze math for GHRS is unforgiving, with limited offers and rising bids potentially leading to a clearing price explosion.
A rumored synthetic layer could exacerbate the squeeze, implying more forced demand hiding behind the scenes.
Even a small fraction of the rumored 60M synthetic shares could lead to an absurd "covering demand" vs "available supply" ratio, potentially rewriting the chart in a single session.

Bearish· Feb 4

$GHRS has seen a significant decline in price, with some users noting a drop from $20 to $14.40.
Some users are expressing concerns about the company's transparency, with one user mentioning that a recent document posted by the company did not have actual numbers populated in certain sections.
The large volume of shares being sold by users, including 135k shares dumped and 2300 shares shorted, suggests that many are bearish on the asset's prospects.

Generated by AI

Topics

Of the messages about GHRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	96.15%	89.78%
Technical Analysis	—	100%	3.85%	2.06%
Analysts	—	0%	0%	2.94%
Controversies	—	0%	0%	3.46%
Earnings	—	0%	0%	0.88%
Macro	—	0%	0%	0.88%

Apr 20

GH Research PLC's stock $GHRS is up 20% in premarket after the FDA lifted the clinical hold on their IND for inhaled mebufotenin treatment GH001.
GH Research PLC is developing GH001, a treatment for treatment-resistant depression, with Phase 3 set to kick off in 2026.
The company's stock may have benefited from a White House executive order easing the pathway to approval for psychedelic treatments, which includes GH001.

Generated by AI

Community

Of the messages about GHRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	74.91%	47.41%
Newcomers	—	0%	25.09%	52.59%

Regulars· Jan 5

The FDA has lifted the clinical hold on GH001, clearing the path for the global phase 3 initiation in 2026.
GH Research needs to complete the phase 1 PK trial with the proprietary device and seek FDA alignment on the global phase 3 program before initiating the phase 3 trial in Q2 2026.
GHRS is trading up 35%+ in pre-market trading and has formed a tight pennant, with the potential for a move if it breaks out with volume.

Newcomers· Jul 17

GHRS has huge potential for the treatment of multiple applications, including pain, depression, and anxiety, with its pipeline drug Ketamir-2 offering similar relief as ketamine without being a controlled substance.
The company's recent move, up 40-44%, is promising, and its potential for a successful market entry is extreme, with a focus on treatment applications.
The newcomer is cautious about ATAI and its potential impact on GHRS, warning that if the deal fails, ATAI may drop to $1, and that strategic investors may have been warned to exit at $9.

Generated by AI

News

GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

Initiate coverage on GH Research: Buy rating as FDA hold lifts for GH001 TRD, Phase 3 in 2026. Click for more on GHRS stock.

9d agoSeeking Alpha

Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

Recently published Postpartum Depression Market Insights report includes a comprehensive understanding of current treatment practices, postpartum depression emerging drugs, market share of individual therapies, and current and forecasted market size from 2022 to 2036, segmented into leading markets [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

1mo agoYahoo Finance

H.C. Wainwright reiterates GH Research stock rating on FDA progress

1mo agoInvesting.com

RBC Capital Remains a Buy on GH Research (GHRS)

Tipranks Press Release.

1mo agoThe Globe and Mail

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

Detailed price information for Scholar Rock Holding Corp (SRRK-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

GH Research stock hits all-time high at 31.41 USD

1mo agoInvesting.com

Also Discussed

Investors talking about GHRS also mention

#	Name	Attention
1	Compass Pathways plc - ADRCMPS	0.03%+0.02
2	ATA Inc-ChinaATAI	0%new
3	AdvisorShares Psychedelics ETFPSIL	0.02%+0.01
4	Cybin Inc.CYBN	0.01%+0
5	Definium Therapeutics, Inc.MNMD	0%+0
6	GBNH - Greenbrook TMS Inc.	——
7	Bright Minds Biosciences Inc.DRUG	0%new
8	Relmada Therapeutics Inc.RLMD	0%0
9	Alto Neuroscience Inc.ANRO	0%new
10	Silo Pharma Inc.SILO	0%new

GH Research PLC

Healthcare
Biotechnology

GH Research PLC is a clinical-stage biopharmaceutical company focused on developing treatments for psychiatric and neurological disorders, with an initial emphasis on depression and treatment-resistant depression. Its current pipeline centers on mebufotenin-based therapies, including GH001, an inhalable product candidate being studied for treatment-resistant depression, bipolar II disorder, and postpartum depression, and GH002, an intravenous candidate in early clinical development. The company is centered on research and development and works to advance novel therapeutic options for mental health conditions with significant unmet medical need. Based in Dublin, Ireland, GH Research PLC is positioned in the broader healthcare and biotechnology markets as a specialist developer of psychedelic-inspired medicines.

Website

Location

Joshua Dawson House

Dublin, D02 RY95

Ireland

Social

What share of all stock conversation is about GHRS?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jul 17

GH Research PLC (GHRS) had a good move, with a 40-44% increase, and the outlook is promising if they go to market without making a mistake.
The company is developing Ketamir-2, a psychedelic treatment for pain, depression, and anxiety, which is not classified as a controlled substance, making it easier for doctors to prescribe.
The user sold their 10k shares of GHRS and will focus on other stocks, but notes that the company's phase 3 data in Q4 is promising and may lead to a large move.

Generated by AI

Sentiment

Of the messages about GHRS that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	100% 0	95.98% +17.3
Bearish	—	—	0% 0	4.02% -17.3

Bullish· Jan 8

The microcap squeeze math for GHRS is unforgiving, with limited offers and rising bids potentially leading to a clearing price explosion.
A rumored synthetic layer could exacerbate the squeeze, implying more forced demand hiding behind the scenes.
Even a small fraction of the rumored 60M synthetic shares could lead to an absurd "covering demand" vs "available supply" ratio, potentially rewriting the chart in a single session.

Bearish· Feb 4

$GHRS has seen a significant decline in price, with some users noting a drop from $20 to $14.40.
Some users are expressing concerns about the company's transparency, with one user mentioning that a recent document posted by the company did not have actual numbers populated in certain sections.
The large volume of shares being sold by users, including 135k shares dumped and 2300 shares shorted, suggests that many are bearish on the asset's prospects.

Generated by AI

Topics

Of the messages about GHRS that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	96.15%	89.78%
Technical Analysis	—	100%	3.85%	2.06%
Analysts	—	0%	0%	2.94%
Controversies	—	0%	0%	3.46%
Earnings	—	0%	0%	0.88%
Macro	—	0%	0%	0.88%

Apr 20

GH Research PLC's stock $GHRS is up 20% in premarket after the FDA lifted the clinical hold on their IND for inhaled mebufotenin treatment GH001.
GH Research PLC is developing GH001, a treatment for treatment-resistant depression, with Phase 3 set to kick off in 2026.
The company's stock may have benefited from a White House executive order easing the pathway to approval for psychedelic treatments, which includes GH001.

Generated by AI

Community

Of the messages about GHRS, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	74.91%	47.41%
Newcomers	—	0%	25.09%	52.59%

Regulars· Jan 5

The FDA has lifted the clinical hold on GH001, clearing the path for the global phase 3 initiation in 2026.
GH Research needs to complete the phase 1 PK trial with the proprietary device and seek FDA alignment on the global phase 3 program before initiating the phase 3 trial in Q2 2026.
GHRS is trading up 35%+ in pre-market trading and has formed a tight pennant, with the potential for a move if it breaks out with volume.

Newcomers· Jul 17

GHRS has huge potential for the treatment of multiple applications, including pain, depression, and anxiety, with its pipeline drug Ketamir-2 offering similar relief as ketamine without being a controlled substance.
The company's recent move, up 40-44%, is promising, and its potential for a successful market entry is extreme, with a focus on treatment applications.
The newcomer is cautious about ATAI and its potential impact on GHRS, warning that if the deal fails, ATAI may drop to $1, and that strategic investors may have been warned to exit at $9.

Generated by AI

GH Research

Social

Jul 17

Bullish· Jan 8

Bearish· Feb 4

Apr 20

Regulars· Jan 5

Newcomers· Jul 17

GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

H.C. Wainwright reiterates GH Research stock rating on FDA progress

RBC Capital Remains a Buy on GH Research (GHRS)

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

GH Research stock hits all-time high at 31.41 USD

Also Discussed

GH Research PLC

Company Information

Location

GH Research: 'Buy' GH001 TRD Advancement Presses On And Expansion Opportunities

Postpartum Depression Market to Evolve During the Forecast Period (2026-2036) with Breakthrough Treatments and Expanding Pipeline Assets | DelveInsight

H.C. Wainwright reiterates GH Research stock rating on FDA progress

RBC Capital Remains a Buy on GH Research (GHRS)

Analysts Have Conflicting Sentiments on These Healthcare Companies: InMode (INMD), GH Research (GHRS) and Scholar Rock Holding (SRRK)

GH Research stock hits all-time high at 31.41 USD

Also Discussed

Social

Jul 17

Bullish· Jan 8

Bearish· Feb 4

Apr 20

Regulars· Jan 5

Newcomers· Jul 17